Codruta Chiuzan, PhD

  • Assistant Professor, Biostatistics at the Columbia University Medical Center
  • Biostatistician, Irving Cancer Center
Profile Headshot


Dr. Chiuzan's statistical research area focuses on development of early phase clinical trial designs (particular interest in cancer targeted and immunotherapeutic agents) and leveraging real-world evidence to improve trial outcomes. She currently serves as one of the main statisticians for the Herbert Irving Comprehensive Cancer Center and as faculty consultant for the Biostatistics Fee-For-Service Consulting Program.

Academic Appointments

  • Assistant Professor, Biostatistics at the Columbia University Medical Center
  • Biostatistician, Irving Cancer Center

Credentials & Experience

Education & Training

  • MS, 2009 University of South Carolina
  • PhD, 2014 Medical University of South Carolina

Honors & Awards

Columbia Public Health Innovation Fund Award, 2020

Calderone Junior Faculty Research Award, 2015


Research Interests

  • Biostatistical Methods
  • Chronic disease
  • Public Health Education

Selected Publications

Shu C, Gainor J, Awad M, Chiuzan C, Grigg C, Saqi A, Rizvi N. Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial, Lancet, 2020, 21(6):786-795.

Chiuzan C, O'Connell N. Innovative Phase I Trials. Book Chapter In: Textbook of Clinical Trials in Oncology: A Statistical Perspective, ed. Halabi S & Michiels S, Chapman and Hall/CRC Press, 1st edition, 2019.

Amengual JE, Lichtenstein R, Lue J, Sawas A, Deng C, Lichtenstein E, Chiuzan C, Khan K, Atkins L, Rada A, Kim HA, et al. A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma. Blood 2018, 131(4):397-407.

Chiuzan C, Elizabeth Garrett-Mayer & Michael Nishimura. An adaptive dose-finding design based on both safety and immunologic responses in cancer clinical trials, Statistics in Biopharmaceutical Research, 2018, 10(3):185-195.

Wages NA, Chiuzan C, Panageas KS, Design considerations for early-phase clinical trials of immune-oncology agents, Journal for ImmunoTherapy of Cancer, 2018, 6(1):81.

Chiuzan, C., Shtaynberger, J., Manji, G. A., Duong, J. K., Schwartz, G. K., Ivanova, A., & Lee, S. M. Dose-finding designs for trials of molecularly targeted agents and immunotherapies. Journal of Biopharmaceutical Statistics, 2017, 27(3), 477-494.

Chiuzan C, Garrett-Mayer E, Yeatts SD. A likelihood-based approach for computing the operating characteristics of the 3+3 phase I clinical trial design with extensions to other A+B designs. Clinical Trials. 2015; 12(1):24-33.

Muennig PA, Quan R, Chiuzan C, Glied S. Considering whether Medicaid is worth the cost: revisiting the Oregon Health Study. Am J Public Health. 2015;105(5):866-71.